Advertisement

Topics

QIAGEN N.V. Company Profile

18:38 EDT 25th September 2018 | BioPortfolio

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2017, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.


News Articles [126 Associated News Articles listed on BioPortfolio]

QIAGEN führt AdnaTest-Flüssigbiopsiekits für Prostata- und Lungenkrebs ein

Auf der Jahreskonferenz der amerikanischen Krebsforschungsgesellschaft AACR werden über 40 Abstracts zu Sample-to-Insight-Lösungen von QIAGEN veröffentlicht QIAGEN N.V. (NYSE: QGEN; Frankfurt Prim....

Qiagen in den Top 5 im TecDAX - ASCO-Meeting startet heute

Die Aktie von Qiagen hat in den vergangenen Wochen ordentlich Gas gegeben. Im Monatsvergleich ist Qiagen sogar mit einer Performance von 13,8 Prozent der fünfstärkste Wert im TecDAX hinter Pfeiffer....

Qiagen Aktie: Die Steuerreform in den USA machte Qiagen einen Strich durch die Rechnung!

Liebe Leser, Qiagen hat die eigenen Prognosen für das abgelaufene Jahr mit einem Umsatzwachstum von 7% auf vergleichbarer Basis (ohne Akquisitionen und Währungseffekte) und einem Gewinn vor Sonderf....

Qiagen: Der unterschätzte Börsen-Altstar!

Lieber Leser, ich habe mich schon in der jüngeren Vergangenheit mehrfach positiv zu Qiagen geäußert und das alles gilt im Grundsatz noch heute. Denn bei Qiagen handelt es sich um einen unterschätz...

QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN's GeneReader NGS System

HILDEN, Germany, and SAN CARLOS, California, March 12, 2018 /PRNewswire/ -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutio...

QIAGEN künftig nicht nur im TecDAX, sondern auch im MDAX vertreten

Im Zuge der Neuordnung der deutschen Aktienmarktindizes wird QIAGEN ab dem 24. September 2018 auch im MDAX geführt. QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, das...

QIAGEN und NeuMoDx kündigen strategische Partnerschaft zur Vermarktung der nächsten Generation voll integrierter molekularer Diagnostiktests an

QIAGEN führt zwei "Sample to Insight"-Systeme in Europa und auf anderen Märkten ein; NeuMoDx vermarktet in den USA Erstes Testmenü für Infektionskrankheiten und LDTs QIAGEN N.V. (NYSE: QGEN; Frank...

QIAGEN to Join Germany's MDAX Index in Addition to TecDAX

QIAGEN to join MDAX as of September 24, 2018, due to reorganization of German stock market indices QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its global shares wi...

Drugs and Medications [0 Results]

None

PubMed Articles [11 Associated PubMed Articles listed on BioPortfolio]

Pre-clinical validation of a next generation sequencing testing panel.

Next Generation Sequencing (NGS) has become a useful tool for gene mutation testing which is required for targeted therapies. The aim of this study was to validate the GeneRead QIAact Actionable Insig...

Early viral-specific T-cell testing predicts late Cytomegalovirus reactivation following Liver Transplantation.

Although antiviral prophylaxis is effective in preventing early cytomegalovirus (CMV) reactivation following liver transplantation (OLT), it predisposes patients to late CMV after prophylaxis has ceas...

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.

: With the integration of various targeted therapies into the clinical management of patients with advanced lung adenocarcinoma, next-generation sequencing (NGS) has become the technology of choice an...

Comparative evaluation of a new magnetic bead-based DNA extraction method from fecal samples for downstream next-generation 16S rRNA gene sequencing.

We are colonized by a vast population of genetically diverse microbes, the majority of which are unculturable bacteria that reside within the gastrointestinal tract. As affordable, advanced next-gener...

Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.

Pediatric HSCT recipients are at high risk for CMV reactivation due to their immature immune system and therapy following transplantation. Reconstitution of CMV-specific T-cell immunity is associated ...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

To assess and compare the performance of the HR HPV HC2® test (Qiagen/Digene) and the APTIMA® HPV Assay (Hologic) using LBC Specimens (ThinPrep® Pap Test) for the detection of HPV infec...

Candidate Gene Screening for Attention Deficit/Hyperactive Disorder (ADHD)

Source: Sample bank of Xijing Hospital and Children's Hospital Affiliated to Soochow University; Sample form: Whole blood; Estimated number of samples: 100 patients with ADHD and age, sex ...

GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps

Colorectal cancer ist the 2nd most leading cancer among men and women in germany. Screening colonoscopy has the potential to detect premalignant lesions. By endoscopical resection of these...

Companies [12 Associated Companies listed on BioPortfolio]

Plexus Corp.

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological s...

QIAGEN GmbH

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samp...

QIAGEN N.V.

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samp...

QIAGEN QIAGEN

QIAGEN NV

More Information about "QIAGEN N.V." on BioPortfolio

We have published hundreds of QIAGEN N.V. news stories on BioPortfolio along with dozens of QIAGEN N.V. Clinical Trials and PubMed Articles about QIAGEN N.V. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of QIAGEN N.V. Companies in our database. You can also find out about relevant QIAGEN N.V. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record